{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.070454","value":"1.53342"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.354164","value":"1.01436"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.571063","value":"0.44840"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.232066","value":"0.29952"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.481822","value":"0.33012"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.330561","value":"0.18411"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Week 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.013461","value":"0.00377"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.106080","value":"0.01599"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.132190","value":"0.02040"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"ABL= Abelson leukemia virus and BCR=Break point cluster region. The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.","dispersionType":"Standard Deviation","groups":[{"description":"If a patient had a confirmed loss of MR4 (two consecutive BCR-ABL1 \\>0.01% IS) or loss of MMR (BCR-ABL1 \\>0.1% IS) in the TFR phase, the patient restarted nilotinib treatment.","id":"OG000","title":"NTRI Phase"}],"paramType":"MEAN","populationDescription":"Nilotinib treatment re-initiation (NTRI) Safety set: Patients who received at least 1 dose of study medication during treatment re-initiation phase after the TFR phase","reportingStatus":"POSTED","timeFrame":"re-start of nilotinib up to approximately 48 weeks","title":"BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)","type":"SECONDARY","unitOfMeasure":"Percent"}